Other Events ·
Bone Biologics Corporation received a notice from Nasdaq indicating it no longer meets the minimum bid price…
BBLGBone Biologics Corp
Bone Biologics Corporation received a notice from Nasdaq indicating it no longer meets the minimum bid price requirement of $1 per share for its common stock. The company has an 180-day compliance period ending March 9, 2027, to regain compliance by maintaining a closing bid price of at least $1 for ten consecutive business days. Failure to comply may result in delisting, though the company intends to seek shareholder approval for a reverse stock split as a potential remedy. Bone Biologics Corporation operates in the biotechnology industry, focusing on regenerative medicine and tissue engineering solutions.